Also known as: Vertex, Vertex Pharmaceuticals
Vertex Pharmaceuticals is an American biopharmaceutical company focused on developing and commercializing medicines for serious diseases. It is best known for its cystic fibrosis franchise and has expanded into cell and genetic therapy programs.
Moderna posted a narrower-than-expected Q2 loss, with mFLUSIVA awaiting an FDA decision and a Phase 3 norovirus trial missing early success criteria. It reaffirmed 2026 revenue growth and cash guidance.
FBT biotech ETF is up 20.35% YTD and 53.20% over one year, beating category averages and IBB. Its concentrated equal-weight 30-stock portfolio carries a 0.55% expense ratio and $2.9B AUM.
U.S. biotech IPOs have returned 55% on average this year, crushing the broader IPO market. Nvidia exited Recursion as ARK Invest bought shares, while Revolution Medicines gained 132% on strong pancreatic cancer data.
IBBQ posted a 43.6% one-year return and 38% max drawdown, while IBB has $9.61B AUM and no dividends. IBBQ outperformed VHT and IXJ over one year but with higher volatility.
FDA granted traditional approval to Novartis' Fabhalta (iptacopan) for IgA nephropathy. Phase 3 APPLAUSE-IgAN data showed eGFR decline slowed by 48% versus placebo over two years.
The acute pain market reached $4.5B in 2025, with 98% of pain drugs generic. Voltage-gated sodium channel inhibitors like Journavx offer non-opioid relief, while 39% of the pipeline uses non-small-molecule modalities.
Crispr Therapeutics AG trades at $47.78 with a $4.78B market cap, while Moderna trades at $61.82 with a $25.06B market cap, about 5.2 times larger. Both face losses, but CRISPR's Casgevy approval and Moderna's pipeline advances shape divergent analyst outlooks.
Vertex Pharmaceuticals dominates cystic fibrosis therapies with TRIKAFTA/KAFTRIO generating $2.57 billion in Q4 2025 and ALYFTREK ramping to $380.1 million. The company posted strong free cash flow of $3.19 billion in 2025 and is expanding into pain, kidney disease, and gene-editing therapies.
Vertex's Phase 3 RAINIER trial of povetacicept in IgA nephropathy met its primary endpoint with a 52% UPCR reduction. The FDA granted rolling review, and Vertex plans full BLA submission by end of March. Shares rose on the news and analyst upgrades.
CRISPR Therapeutics said CASGEVY launch momentum is building and multiple pipeline assets could generate data in the next 12 to 18 months. The company also highlighted zugo-cel progress in oncology and autoimmune disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07700225 |
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension |
RECRUITING | |
| NCT07654296 |
Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery |
NOT_YET_RECRUITING | PHASE3 |
| NCT07624526 |
Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty |
NOT_YET_RECRUITING | PHASE4 |
| NCT07584434 |
A Phase 1, First-in-human Study of VX-433 |
RECRUITING | PHASE1 |
| NCT07570069 |
Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants |
COMPLETED | PHASE1 |
| NCT07538570 |
Evaluation of Pain Treatment After Total Knee Arthroplasty |
RECRUITING | PHASE4 |
| NCT07501702 |
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis |
RECRUITING | PHASE2 |
| NCT07463430 |
Suzetrigine for Non-Mastectomy Breast Surgery |
ENROLLING_BY_INVITATION | PHASE4 |
| NCT07437105 |
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants |
RECRUITING | PHASE1 |
| NCT07378865 |
Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants |
RECRUITING | PHASE1 |
